Molecular landscapes of the tumor tissues before and after Palbociclib treatment were obtained by IHC and WES for investigating potential responsive and drug-resistant markers indicating the administration or withdrawal of CDK4/6 inhibitor. The gene discussed is CDK4; the disease is neoplasm.